2265-90-9

Basic information

• Product Name: 4,6-Dinitro-2-fluorophenol
• Synonyms: 4,6-Dinitro-2-fluorophenol
• CAS NO: 2265-90-9
• Molecular Formula: C₆H₃FN₂O₅
• Molecular Weight: 202.0968232
• EINECS: -0
• Mol File: 2265-90-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 102 °C
• Boiling Point: 296.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.745±0.06 g/cm3(Predicted)
• PKA: 2.65±0.44(Predicted)
• CAS DataBase Reference: 4,6-Dinitro-2-fluorophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dinitro-2-fluorophenol(2265-90-9)
• EPA Substance Registry System: 4,6-Dinitro-2-fluorophenol(2265-90-9)

Safety Data

• Hazardous Substances Data: 2265-90-9(Hazardous Substances Data)

Upstream product

• 367-12-4 2-fluorophenol 
• 321-28-8 1-fluoro-2-methoxybenzene 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 462-06-6 fluorobenzene 
• 451-80-9 1-ethoxy-2-fluoro-benzene 
• 3324-58-1 sodium picrate 

Downstream Products

• 1309833-31-5 4-bromo-3-fluoro-5-nitroaniline 
• 344-78-5 6-fluoro-2,4-dinitroanisole 
• 1356493-53-2 4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)benzenamine 
• 1356493-52-1 1-(2-cyclopropyl-3-fluoro-5-nitrophenyl)-1H-tetrazole 
• 1356493-33-8 N₂-(4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)phenyl)-5-fluoro-N₄-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine 
• 1356493-32-7 2-(4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)phenylamino)-4-(2,2,6,6-tetramethylpiperidin-4-ylamino)pyrimidine-5-carbonitrile 
• 1309832-54-9 1-(5-Amino-2-cyclopropyl-3-fluorophenyl)-4-methyl-5H-tetrazol-5-one 
• 1309832-53-8 1-(2-Cyclopropyl-3-fluoro-5-nitrophenyl)-4-methyl-5H-tetrazol-5-one 
• 1309832-52-7 1-(2-cyclopropyl-3-fluoro-5-nitrophenyl)-4,5-dihydro-5H-tetrazol-5-one 
• 1309832-51-6 2-Cyclopropyl-3-fluoro-5-nitrophenylisocyanate 
• 1309832-50-5 2-cyclopropyl-3-fluoro-5-nitroaniline 
• 1309832-49-2 2-bromo-3-fluoro-5-nitroaniline 
• 1309832-48-1 2-bromo-1-fluoro-3,5-dinitrobenzene 
• 367-78-2 2-Fluor-4,6-dinitro-anilin 

Relevant articles and documents

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.